Itraconazole is an antifungal agent included in the triazole pharmacological classification that belongs to the BCS class II, characterized by a low solubility in an aqueous medium (of 1 ng/mL, at neutral pH), which is frequently translated in a low oral bioavailability but with a high permeability. In this sense, it is necessary to find solutions to increase/improve the solubility of itraconazole in the aqueous environment. The main purpose of this study is the preparation and analysis of five different guest–host inclusion complexes containing intraconazole. Initially, a blind docking process was carried out to determine the interactions between itraconazole and the selected cyclodextrins. The second step of the study was to find out if the active pharmaceutical ingredient was entrapped in the cavity of the cyclodextrin, by using spectroscopic and thermal techniques. Also, the antifungal activity of the inclusion complexes was studied to examine if the entrapment of itraconazole influences the therapeutic effect. The results showed that the active substance was entrapped in the cavity of the cyclodextrins, with a molar ratio of 1:3 (itraconazole–cyclodextrin), and that the therapeutic effect was not influenced by the entrapment.
Carvedilol (CARV) is a nonselective beta and alpha-1 adrenoceptor antagonist commonly indicated for chronic heart failure and hypertension. Its clinical potential is limited by its low aqueous solubility, resulting in poor bioavailability. Encapsulation of CARV by cyclodextrins (CDs) was performed to exceed its solubility-related barriers. This study examines the impact of the CD type and ethanol, as a co-solvent used in the preparation step, on the complexation of CARV with two β-CD derivatives. The inclusion complexes (ICs) were prepared employing the kneading method and investigated using different analytical techniques, including thermoanalytical methods, powder X-ray diffractometry (PXRD), universal attenuated total reflectance Fourier transform infrared (UATR-FTIR) spectroscopy, UV spectroscopy and saturation solubility studies. The binary products of CARV with heptakis(2,6-di-O-methyl)-β-cyclodextrin (DM-β-CD) and randomly methylated β-cyclodextrin (RM-β-CD) exhibit different thermal behavior, different FTIR spectral and diffractometric profiles from those of the parent compounds, emphasizing the interaction between the components and the IC formation. CARV solubility increased 1.78 to 3.32 times as a result of drug complexation with CDs. Analytical data indicate a significant influence of both solvent systems and CD type on the IC solubility, highlighting the CARV/DM-β-CD IC as a promising entity for further research to obtain new formulations containing CARV with improved bioavailability.
Sulfobutyl-ether-beta-cyclodextrin sodium salt (SBECD) is a modified cyclodextrin widely used in the pharmaceutical industry to enhance the solubility and stability of poorly water-soluble drugs. As a derivative of beta-cyclodextrin, it is produced by introducing sulfobutyl ether groups into the beta-cyclodextrin molecule, which significantly increases its water solubility and decreases its toxicity compared to unmodified cyclodextrins. This study investigates the spectral and PXR diffraction characterization of SBECD, its thermal stability profile, and decomposition mechanism using isoconversional methods. Since the simple ASTM E698 method does not provide realistic data, the Flynn–Wall–Ozawa, Friedman, and NPK methods were employed, leading to the kinetic triplet that characterizes the oxidative thermolysis of this compound.